纳米药物用于糖尿病病的管理:目前的进展和前景
Paramita Paul1, Leena Chacko2, Tarun K Dua1
1Department of Pharmaceutical Technology, University of North Bengal, Darjeeling, India.
Frontiers in endocrinology
|November 29, 2023
概括
糖尿病病 (DN) 是糖尿病 (DM) 的并发症,迫切需要更好的治疗方法. 纳米粒子为诊断和治疗DN提供了有前途的新方法,改善了患者的治疗结果.
科学领域:
- 生物医学工程 生物医学工程
- 纳米技术纳米技术
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病病 (DN) 是糖尿病 (DM) 的主要微血管并发症,导致末期病.
- 目前对DN的治疗受限于药物溶解性差,生物可用性低,高毒性和患者遵守性差.
- 早期检测和有效的治疗对于管理DN至关重要,但实现这一目标仍然是一个挑战.
研究的目的:
- 审查纳米系统作为DN诊断和治疗的超神论平台的潜力.
- 突出纳米颗粒在克服传统DN治疗的局限性方面的优势.
- 为DN管理提供各种纳米载体的最新概述.
主要方法:
- 对DN纳米颗粒的最新研究的文献综述.
- 分析纳米载体特性及其在DN诊断和治疗中的应用.
- 讨论纳米平台提供的优势,包括特定站点的交付和改善的药理动力学.
主要成果:
- 纳米系统显示显著的承诺作为DN的theranostic平台.
- 与传统疗法相比,纳米粒子提供了改进的诊断,特定部位的药物输送,以及增强的药物动力学概况.
- 各种纳米载体正在探索它们在DN管理中的潜力.
结论:
- 纳米粒子代表了一种新的,有前途的方法来诊断和治疗糖尿病病.
- 纳米平台的独特特性解决了当前DN疗法的关键挑战,为改善患者护理铺平了道路.
- 对纳米载体应用的进一步研究对推进DN管理策略具有重大潜力.
更多相关视频
10:37Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
168
07:01Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
Published on: May 10, 2022
1.6K
相关概念视频
01:15Diabetes: Management and Pharmacotherapy
289
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
289
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
209
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
209
01:06Oral Hypoglycemic Agents: Glinides
157
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
157
01:23Dipeptidyl Peptidase 4 Inhibitors
190
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
190
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
01:16Antihypertensive Drugs: Action of Diuretics
786
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
786